Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 10/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 10/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 10/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 10/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 10/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14439211 | 1.00 | HPGD (0.58) | HPGDGAAALDH1A1SMN1; SMN2CHRM2 | |
| SCHEMBL420108 | 1.00 | HPGD (0.58) | HPGDGAAALDH1A1SMN1; SMN2CHRM2 | |
| SCHEMBL3436833 | 0.93 | — | — | |
| SCHEMBL6097894 | 0.93 | — | — | |
| SCHEMBL419842 | 0.93 | — | — | |
| Propane SCHEMBL7055719 | 0.86 | HPGD (0.46) | HPGDGAAALDH1A1SMN1; SMN2CHRM2 | |
| Benzene SCHEMBL9854132 | 0.86 | HPGD (0.50) | HPGDGAAALDH1A1SMN1; SMN2POLB | |
| SCHEMBL4028484 | 0.84 | HPGD (0.60) | HPGDGAAALDH1A1SMN1; SMN2POLB | |
| SCHEMBL17464820 | 0.83 | — | — | |
| SCHEMBL14436404 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151638-A2 | COMPOUNDS FOR FGFRS INHIBITORS | COGENT BIOSCIENCES, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20230365561-A1 | BETA-LACTAMASE INHIBITORS AND THEIR PREPARATION | NINGXIA ACADEMY OF AGRICULTURE AND FORESTRY SCIENCES (CN) | 2023-11-16 | — | — | US | disclosed |
| US-11530193-B2 | Kinase inhibitors | THE UNIVERSITY OF MANCHESTER (GB) | 2022-12-20 | — | — | US | disclosed |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-10-29 | — | — | US | disclosed |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-14 | — | — | US | disclosed |
| US-20180134717-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
| EP-3235820-A1 | PYRROLOBENZODIAZEPINES AND ANTIBODY DISULFIDE CONJUGATES THEREOF | Genentech, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016044560-A1 | PYRROLOBENZODIAZEPINES AND ANTIBODY DISULFIDE CONJUGATES THEREOF | GENENTECH, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20160074527-A1 | PYRROLOBENZODIAZEPINES AND ANTIBODY DISULFIDE CONJUGATES THEREOF | GENENTECH, INC. | 2016-03-17 | — | — | US | disclosed |
| US-20130266595-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| EP-0576592-B1 | OLIGOSACCHARIDE ENZYME SUBSTRATES AND INHIBITORS: METHODS AND COMPOSITIONS | SCRIPPS RESEARCH INST (US) | 2000-05-31 | — | — | EP | disclosed |
| US-5759823-A | MIXING IN AQUEOUS MEDIUM ACTIVATED DONOR MONOSACCHARIDE WITH ACCEPTOR SACCHARIDE IN PRESENCE OF GLYCOSYLTRANSFERASE, MAINTAINING TO GLYCOSYLATE ACCEPTOR SACCHARIDE | SCRIPPS RESEARCH INSTITUTE (US) | 1998-06-02 | — | — | US | disclosed |
| US-5596005-A | GLYCOSIDASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1997-01-21 | — | — | US | disclosed |
| US-5593887-A | Oligosaccharide enzyme substrates and inhibitors: methods and compositions | THE SCRIPPS RESEARCH INSTITUTE (US) | 1997-01-14 | — | — | US | disclosed |
| EP-0576592-A4 | OLIGOSACCHARIDE ENZYME SUBSTRATES AND INHIBITORS: METHODS AND COMPOSITIONS | SCRIPPS RESEARCH INST (US) | 1996-01-24 | — | — | EP | disclosed |
| US-5461143-A | Oligosaccharide enzyme substrates and inhibitors: methods and compositions | THE SCRIPPS RESEARCH INSTITUTE (US) | 1995-10-24 | — | — | US | disclosed |
| EP-0576592-A1 | OLIGOSACCHARIDE ENZYME SUBSTRATES AND INHIBITORS: METHODS AND COMPOSITIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1994-01-05 | — | — | EP | disclosed |
| US-5276120-A | Reductively cyclizing an azido-substituted alpha-ketose phosphate; palladium catalyzed | THE SCRIPPS RESEARCH INSTITUTE (US) | 1994-01-04 | — | — | US | disclosed |
| WO-1992021657-A1 | OMEGA-DEOXY-AZASUGARS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1992-12-10 | — | — | WO | disclosed |
| WO-1992016640-A1 | OLIGOSACCHARIDE ENZYME SUBSTRATES AND INHIBITORS: METHODS AND COMPOSITIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1992-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130266595-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD79B, BCL6B, DRD1 | HPGD 1656/4885GAA 3121/4885ALDH1A1 1055/4885 |
| US-20180134717-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | HDAC10, PBDC1, PDCD10 | HPGD 1000/4885GAA 2546/4885ALDH1A1 1192/4885 |
| US-11530193-B2 | Kinase inhibitors | CAMKK2, CAMK1, CAMKK1 | HPGD 1397/4885GAA 2326/4885ALDH1A1 2394/4885 |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | HPGD 3679/4885GAA 4612/4885ALDH1A1 1598/4885 |
| US-20230365561-A1 | BETA-LACTAMASE INHIBITORS AND THEIR PREPARATION | MGAM, LCT, GANAB | HPGD 873/4885GAA 4/4885ALDH1A1 315/4885 |
| US-20160074527-A1 | PYRROLOBENZODIAZEPINES AND ANTIBODY DISULFIDE CONJUGATES THEREOF | CD79B, PA2G4, SBDS | HPGD 2048/4885GAA 3806/4885ALDH1A1 673/4885 |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | HPGD 3679/4885GAA 4612/4885ALDH1A1 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.